

McKeown, T.: Validation of Screening Procedures, in *Screening in Medicine: Reviewing the Evidence: A Collection of Essays*. (London: Oxford University Press, 1968), pp. 1-13.

McKeown, T., and E. G. Knox, The Framework Required for Validation of Prescriptive Screening, in *Screening in Medicine: Reviewing the Evidence: A Collection of Essays*. (London: Oxford University Press, 1968), pp. 159-173.

McKeown, T., and C. R. Lowe: *An Introduction to Social Medicine*. (Philadelphia: F. A. Davis, 1966), pp. 86-87.

*Report of the International Conference on Adverse Reactions Reporting Systems*. National Academy of Sciences, Washington, D.C. 1971.

Riggan, W. B., D. I. Hammer, J. F. Finklea, V. Hasselblad, C. R. Sharp, R. M. Burton, and C. M. Shy, CHESS, A Community Health and Environmental Surveillance System. *Proceedings of the Sixth Berkeley Symposium on Mathematical Statistics and Probability, vol. VI Effects of Pollution on Health*. (Berkeley: University of California Press, 1972), pp. 111-123.

Sartwell, P. E. (ed.), *Maxcy-Rosenow Preventive Medicine and Public Health*, 9th ed. (New York: Appleton-Century-Crofts, 1965), pp. 16-19.

Shapiro, S., P. Strax, and L. Venet. 1971. Periodic breast cancer screening in reducing mortality from breast cancer. *J. Am. Med. Assoc.*, **215**:1777-1785.

Terris, M. 1948. Relation of economic status to tuberculosis mortality by age and sex. *Am. J. Public Health*, **38**:1061-1070.

Thorner, R. M. 1969. Whither multiphasic screening? *New Engl. J. Med.*, **280**:1037-1042.

Thorner, R. M. and Q. R. Remein, *Principles and Procedures in the Evaluation of Screening for Disease*. U.S. Department of Health, Education, and Welfare. Public Health Monograph no. 67, 1961.

White, K. L., T. F. Williams, B. G. Greenberg. 1961. The ecology of medical care. *New Engl. J. Med.*, **265**:885-892.

Whittenberger, J. L., The physical and chemical environment, in *Preventive Medicine*, edited by D. W. Clark, B. MacMahon, (Boston: Little, Brown, 1967), pp. 630-638.

Wilson, J. M. G. November 1968.: The evaluation of the worth of early disease detection. *J. Roy. Coll. Gen. Pract., Suppl.*, **2**:48-57.

Winkelstein, W., Jr. 1972. Epidemiological considerations underlying the allocation of health and disease care resources. *Intern. J. Epidemiology*, **1**:69-74.

# Index

Accidents:  
 automobile, 74, 98-102, 197  
 pedestrians fatally injured by, 98-102, 196  
 epidemiologists' attention to, 202  
 injuries from, 91  
 prevention of, 98

Adjustment, 13, 158-161  
 direct, 159-161  
 indirect, 159-161

After-the-fact explanations, 118

Age:  
 adjustment, 13, 158-161  
 current versus cohort tabulations, 54-58  
 as factor in disease occurrence, 53-54, 99, 102, 109, 112, 197-198

Age matching of controls, 92-93

Age standardization (see Adjustment)

Agent, disease-producing, 3, 68, 74

Air pollution:  
 in Berlin, New Hampshire, respiratory disease study, 80-83  
 producing short-term time trends in disease, 67  
 as related to urban-rural differences in lung cancer, 64

Alcohol consumption:  
 in relation both to disease and cigarette smoking, 165  
 in relation to automobile accidents, 74, 98-99, 101-102, 196  
 sex differences in, 58  
 underestimation of, 36

Alcoholism:  
 as etiologic factor for head injuries and cirrhosis of liver, 166  
 as etiologic factor for tuberculosis, 3

Analysis of covariance, 161

Analytic studies (see Studies)

**Angina pectoris (see Heart disease)**  
**Animals**, findings in, as related to man, 3, 114  
**Antibodies**:  
 resulting from poliomyelitis vaccination, 128-130  
 as source of immunity, 68  
**Arthritis**, degenerative, 48-49, 54  
**Associations between attributes and disease**, 94, 150-151  
 (See also Statistical associations)  
**Atherosclerosis**:  
 biologic mechanisms in, 164  
 epidemiologic study of, 109-113, 118  
 spurious association with handgrip strength, 155  
**Atrial fibrillation (see Heart disease)**  
**Attack rates**, 67, 203  
**Attributes**:  
 qualitative, 13, 21, 94  
 quantitative, 13-21, 94  
 matching of, 93  
**Autopsy**:  
 coronary atherosclerosis at, 118  
 disease associations noted at, 166  
 in poliomyelitis vaccine trial, 129  
**Average life expectancy (see Life expectancy)**  
  
**Berlin, New Hampshire**, study of respiratory disease, 81-84  
**Bias**:  
 in case-control studies, 90, 92  
 in comparing invalid means, 24  
 in evaluating health-care innovations, 216  
 in experimental studies, 126, 136  
 in incidence studies, 104, 108-109  
 in medical literature, 198  
 in one's own study, 185  
 from poor quality data, 41  
 in sampling, 79  
 in therapeutic trials, 142  
**Bilirubin breakdown due to light**, 37  
**Biostatistics (see Statistics)**  
**Blind experiments**, 126-128  
**Blood pressure**:  
 absence of normal cutoff point in, 193  
 abstracting from medical records, 180-181

**Blood pressure**:  
 age and, 93  
 comparison using quantiles, 20  
 in coronary heart disease, 13, 58, 84-85, 112-113, 141, 193-195  
 digit preference, 27-28  
 elevated (see Hypertension)  
 in Evans County, Georgia, study, 84-85  
 in Framingham Heart Study, 13, 112-113  
 in practicing preventive medicine, 194-195  
 as quantitative attribute, 13  
 sources of variation in, 25  
 stroke and, 38-42, 109  
 in study of observer error, 27  
 (See also Hypertension)  
**Blood specimens and tests**, 129, 131, 133, 194  
**Bronchitis (see Chronic bronchitis)**  
  
**Cancer**:  
 bias in a study of, 109  
 of bladder, 165  
 of breast, 54-55, 59, 62-63  
 screening for, 213  
 as cause of death, 117, 133  
 of colon, 6, 62-63, 167  
 family history of, 109  
 of lung, 3, 11-12, 64, 74-75, 163, 165, 208  
 screening for, 213  
 of prostate, 53  
 relationship to emotional state, 81, 92, 108  
 of skin, 58  
 of stomach, 8, 60, 62-63, 74, 208  
 of uterine cervix, 2, 59  
 (See also Leukemia)  
**Cardiovascular disease**, 117, 133, 192  
 (See also Heart disease; Hypertension; Peripheral vascular disease; Strokes)  
**Case-control studies (see Studies)**  
**Case identification (ascertainment)**, 48, 88-90, 95  
**"Cases" as term in research versus clinical setting**, 88-89  
**Cause-and-effect relationship**, 121, 162-166

**Causation of disease**, 1-5, 43-44, 58, 104, 108, 138, 162-166  
**Causes of death**, 32-34, 116-118  
**Census tracts**, 64, 66  
**Cerebrovascular disease (see Strokes)**  
**Checkups**, 2, 134-136, 216  
**Cholesterol**:  
 absence of normal cutoff point in, 193-194  
 changes in, 106, 108  
 comparison using quantiles, 20  
 in coronary heart disease, 20-21, 85, 106, 162, 193-195, 209, 215  
 in diet, 164, 209  
 in Evans County, Georgia, study, 85  
 in Framingham Heart Study, 24-25, 162  
 in practicing preventive medicine, 194-195, 209  
 in screening, 215  
 (See also Lipid levels in serum)  
**Cholesterol phospholipid ratio**, 20-21  
**Chronic bronchitis**, 58, 60, 82-83  
**Chronic disease (conditions)**, 36-37, 67  
 epidemiologists' attention to, 202  
**Cigarette smoking**:  
 assessed by questionnaire, 34-35  
 avoidance of, by cooperative subjects, 134-135  
 in Berlin, New Hampshire, respiratory disease study, 81-84  
 as bias source in cancer study, 109  
 categories, 80  
 in chronic bronchitis, 58, 81-84  
 in coronary heart disease, 58, 113, 151-153, 163, 165, 193-195  
 in lung cancer, 3, 12-13, 64, 74, 150, 163, 165, 170  
 in oral contraceptive study, 97  
 in practicing preventive medicine, 194-195, 209-210  
 sex differences in, 58  
 statistical associations with, 150, 163, 165  
 urban-rural differences in, 64  
**City, areas within**, 64, 66  
**Classification of diseases**, 5-6  
**Clinical history**, 27, 34  
**Clinical observations (see Observations)**  
**Clinical studies**, 2, 138-148  
**Clinician as source of hypotheses**, 84  
  
**Clinicians' views**:  
 of data, 37-38, 42  
 of disease in the community, 210-211  
 of patients, 1-2, 5, 37-38  
 of screening, 213-214  
 of therapy, 142-143  
**Cohort**, 48, 86, 104-105, 107, 116, 119  
**Cohort age tabulations (cohort analysis)**, 54-58  
**Cohort studies (see Studies, incidence)**  
**Communicable period**, 68, 70  
**Computer data banks**, 119  
**Computer**:  
 use with "canned" multivariate analysis program, 161  
 use in data processing, 184  
**Confidentiality of records**, 122  
**Congenital defects**:  
 epidemiologic study of, 202  
 monitoring of, 206  
**Consultation in carrying out a study**, 173-174  
**Contraceptives, oral and thromboembolic disease**, 95-98, 164  
**Control group**, 48  
 in experimental studies, 121-136  
 nonrandom, 124-125, 131-133  
 randomized, 123-125, 131, 133  
 matched controls, 92-93, 96-97, 99-100  
 need for, in claiming treatment benefits, 196  
 "paired" selection of, 93  
 selection of, 90-93, 96-97, 99-100  
**Cooperation of experimental subjects**, 125-126  
**Coronary care units**, 53, 148  
**Coronary heart disease (see Heart disease)**  
**Coroner's reports**, 112  
**Correlation**:  
 built-in, 109  
 coefficient of, 151-152  
 ecological, 153  
 multiple, 161  
**Counts**, 7-8, 13-14  
**Critical reading (see Literature)**  
**Cross-sectional age tabulations**, 54-58  
 of life expectancy 57-58, 117  
**Cross-sectional studies (see Studies, prevalence)**

Crowding:  
and rheumatic fever, 67  
and tuberculosis, 3  
Cycles of disease occurrence, 73-74

Data analysis:  
in case-control studies, 94  
in incidence studies, 107-108  
for one's own study, 181-184  
in prevalence studies, 80

Data banks, 119

Data collection:  
in case-control studies, 93-94  
forms, 174-179, 181  
pre-coded, 177  
in incidence studies, 105-107  
methods for one's own study, 174-181  
pretesting of, 179-181  
in prevalence studies, 79-80

Data processing for one's own study, 174-175, 183-184  
(*See also Computer*)

Data quality, 24

Death:  
age at: mean, 19  
median, 19, 117  
causes of, 32-34, 116-118  
as outcome of disease, 138-139  
sudden (see Sudden death)  
surveillance of, 106

Death certificates, 32, 38, 112, 116, 135

Death rates (see Mortality rates)

Deciles, 19

Definition of diseases, 5-6

Definition of problem to be studied, 169-170

Denominators:  
as central concerns of epidemiology, 8  
changing, 11  
lack of, in spontaneous reporting systems, 206  
need for, in statements about risk, 196-198  
person-year, 107-108  
population, 66  
in rates or proportions, 8

Dental caries, 53, 131-133

Descriptive studies (see Studies)

Diabetes mellitus, 32, 58, 96, 113, 141-142, 175

Diabetes mellitus:  
screening for, 212, 214-215

Diagnosis:  
as observations or data, 30, 32  
as related to apparent disease associations, 166

Diagnoses:  
criteria for, 30, 83, 85, 89, 112, 126, 130  
early, and survival, 148  
epidemiologic aids to, 187-189  
epidemiologic (analytic) studies to improve, 189-191

Diet:  
for changing risk factors, 113, 195  
high animal fat, 84, 164  
in Japan, 62

Dietary history, 85

Digit preference, 27-28

Disability:  
in multiphasic evaluation study, 135-136  
as outcome of disease, 138-139

Discriminant analysis, 161

Disease:  
causation (see Causation of disease)  
duration (see Duration of disease)  
in elderly persons, 53, 113  
monitoring frequency changes, 206  
names, descriptive versus causal, 5-6  
onset times, 67  
outcome, 138-148  
prognosis, 139-140  
reporting, 31

Distributions, 14-22  
cumulative, 14-16, 18-20  
display of, 15-16  
normal or Gaussian, 191  
overlapping of, in healthy and sick persons, 192-193

Double-blind experiments, 126-127

Droplet nuclei, 68

Droplets, 68, 74

Drugs:  
abuse of, 36, 216  
adverse reactions to, 31, 126, 144, 177, 204-207  
monitoring of, 205-207

cohort exposed to, 105

effects on laboratory tests, 37

in experimental studies, 126, 142, 144, 196

Drugs:  
physician's evaluation of, 142  
in practicing preventive medicine, 195, 209  
to prevent atherosclerosis, 113  
recording reasons for administration, 177-178  
therapeutic trials of, 142, 144, 196  
in treating hypertension, 144, 195

Dummy (see Placebo)

Duration of disease, 80-81, 108  
in incidence studies, 108  
in prevalence studies, 80-81

Duration of follow-up in incidence studies, 106-107

Ecological correlations, 153

Education:  
background of subjects of case-control study, 91  
as index of socioeconomic status, 60, 85

Elderly persons' diseases, 53, 113

Electrocardiogram, 85, 111  
abnormalities of, 113  
in diagnosing heart disease, 189  
logistical problems in obtaining, 180

Environment, 3, 23, 62, 109, 140, 209  
changes to prevent disease, 209-210  
hazards in, 34  
detection and evaluation of, 204-207

Epidemics, 31, 67-75  
as appropriate labels for long-term trends, 74-75  
duration of, 70  
investigation of, 201-204, 206  
point source, 70  
time pattern of, 70

Ethical problems:  
in experimental studies, 122-123, 127  
in intentional exposure to radiation, 114  
in observational studies, 122  
in screening, 212

Etiology (see Causation of disease)

Evans County, Georgia, study of cardiovascular disease, 84-86, 105

Examinations:  
to detect disease in a population, 79, 85, 105, 111, 133, 180

Examinations  
physical, 27-28, 111, 119, 129, 134-136

Exercise (see Physical activity)

Experimental (treated) group, 121-136

Experimental studies (see Studies)

Familial aggregation, 111

Family history:  
of cancer, 109  
of coronary heart disease, 113

"Fishing expeditions," 103

Fluoride and dental caries, 53, 131-133, 209

Follow-up:  
of patients with disease, 140-144  
of persons screening positive, 215  
of population for disease development, 48, 105-110, 112, 118  
of subjects in an experiment, 121, 135  
variable periods of, 107

Food:  
contaminated, 70, 203  
as vehicle of disease transmission, 68, 73

Framingham Heart Study, 38, 109-115, 162

Gallbladder disease, 113, 171, 190  
(*See also Gallstones*)

Gallstones, 9, 44-45, 58, 171

Genetics:  
and disease, 58-59  
and migration, 62  
(*See also Inheritance*)

Geographic variation in disease occurrence, 152-153  
(*See also Place*)

Glucose, 194  
method for recording serum level, 175-176

Groups:  
of individuals versus groups of groups, 152-153  
patient versus population, 138-139  
study of, 1-2

Headache:  
as descriptive disease name, 5  
relation to hypertension, 190

Health-care professional (see Clinician)

Health services research, 202, 217  
 Heart disease:  
     angina pectoris, 36, 85, 113, 141, 170  
     atrial fibrillation, 24  
     as cause of death, 32  
     congestive heart failure, 50-51, 145  
     coronary: duration of, in prevalence studies, 80, 105  
         in Evans County, Georgia, study, 84-86, 105  
     in Framingham Heart Study, 20-21, 109-114, 162  
     incidence of, 118  
     in incidence studies, 105-106, 118  
     in Japanese, 62-63  
     mortality and cigarette smoking, 151-153  
     multivariate methods in study of, 161  
     need for epidemiologic study, 2  
     in practicing preventive medicine, 194-195, 209  
     psychological factors in, 170  
     relation to aging, 53-54  
     relation to race, 84-86  
     relation to sex, 58  
     risk factors, 20-21, 58, 109-114, 151-153, 193-195, 215  
     risk screening, 215  
     spurious association with handgrip strength, 155  
     statistical associations with, 162-166  
     diagnosis of, as aided by epidemiology, 188-189  
     myocardial infarction, 3-5, 53, 85, 113, 141, 148, 170, 197, 215  
     rheumatic, 60, 113, 140  
         (See also Rheumatic fever)  
     scleroderma, 147  
 Heat waves producing short-term time trends in disease, 67  
 Hepatitis, 8, 70-73  
 Hernias, 91-92, 167  
 Herniorrhaphy, 49, 92  
 Histogram, 15-16  
 Hospital charts (records), 51, 89  
 Hospitalizations in population follow-up, 106, 112, 135  
 Host (of disease), 3, 68, 74, 98  
 Hyaline membrane disease, study of factors predicting outcome, 141

Hypertension:  
     in coronary heart disease, 112-113, 215  
     effects of detecting, 136  
     effects of treating, 144-145  
     in Evans County, Georgia, study, 84  
     in Framingham Heart Study, 112-113  
     in incidence studies, 118  
     in Japanese, 62  
     in mortality statistics, 32-34  
     predisposing to thromboembolism, 96  
     racial differences in, 59  
     recording history of, 181  
     socioeconomic status in, 60  
     in stroke, 38-42  
     symptoms of, 190  
     Veterans Administration study of, 144-145  
         (See also Blood pressure)  
 Hypotheses for further study:  
     from case-control studies, 103  
     from descriptive studies, 53-54, 59  
     from physicians' observations, 84

Immunity, 68  
     duration of, 53  
     to tuberculosis, 56  
 Immunization, 68-70, 208  
 Inapparent infections, 68  
 Incidence rates (see Rates)  
 Incidence studies (see Studies)  
 Incubation period, 68, 70, 203  
     in chronic noninfectious diseases, 110  
 Infant mortality, 60-61, 133  
 Infections:  
     transmission of, 68  
     upper respiratory, 74  
 Infectious disease, 3, 67-74  
     epidemiologists' attention to, 201-202  
     investigation of epidemics, 201-204  
 Informed consent, 123  
 Inheritance, sex-linked, 58  
     (See also Genetics)  
 International Classification of Diseases, 32  
 International comparisons of disease or mortality rates, 61-64  
 Interpretation:  
     of case-control studies, 94-95  
     of prevalence studies, 80-81

Interquartile range, 20  
 Interviews:  
     to collect data, 36, 82, 90, 94, 96-97, 99-101, 180, 202-203  
     to rule out disease in control subjects, 93

Japan:  
     breast feeding in, 62  
     diet in, 62  
     uniqueness of, regarding certain diseases, 61-64  
 Japanese, epidemiologic study of, in three areas, 64

Kaiser-Permanente Medical Care Program (Kaiser Foundation Health Plan), 34-36, 134-135, 207

Kidney disease:  
     absence of, after poliomyelitis vaccination, 131  
     nephritis, 32-34  
     renal calculi, 89, 92-93  
     renal colic, 89  
     scleroderma, 147

Laboratory data, 37  
     collection in case-control studies, 93  
 Laboratory tests, 38, 111, 189  
     in discriminating diseased from well, 189, 191-194  
     sensitivity of, 192  
     specificity of, 192  
 Leukemia, 105, 117  
 Life expectancy, 57-58  
 Life-insurance-company investigations, 105  
 Life-span and radiation, 114, 117  
 Life table, 57-58  
     method for determining survival curves, 147  
 Lipid levels in serum, 111-113, 164  
     (See also Cholesterol)  
 Literacy and birthplace, 153  
 Literature:  
     critical reading of, 195-200  
     reviewing for a study, 170-171

Liver, cirrhosis of, 9, 58, 143, 165-166  
     (See also Hepatitis)  
 Loss to follow-up, 107, 109  
 Luau, as source of hepatitis epidemic, 72-73  
 Lung disease:  
     obstructive, 82  
     scleroderma, 146-147

Mai-tai punch as hepatitis vehicle, 73  
 Marital status and disease occurrence, 53, 59  
 Matched controls, 92-93  
 Means, 16-17, 19, 22, 24-25, 94, 179  
     comparison of, 24-25  
 Measles epidemic, 68-70  
 Medians, 18-19, 94, 117  
     advantages over means, 19  
 Medical care:  
     emergency, 102  
     limited effects on community health, 207-209  
     new system of, 216  
     studies of, 202  
         (See also specific programs and plans)  
 Medical chart (see Medical records)  
 Medical (clinical) history, 27, 85, 111, 129  
 Medical records, 30-31, 51  
     problems in abstracting, 180-181  
     for ruling out disease in control subjects, 93  
 Medical specialists' observations, 28-30  
 Medicine, as a complex field, 118  
 Menopause, 54, 58-59  
     artificial (surgical), 59  
 Mental illness, as object of epidemiologic study, 202  
 Migration, 62  
 Misclassification of study subjects, effects of, 41-42, 89  
 Morbidity ratios, 12-13, 20-21, 160  
 Mortality:  
     infant, 60-61, 133  
     influence of checkups on, 134, 136  
     life insurance investigations of, 105  
     operative and postoperative, 148  
     radiation exposure and, 114-117  
     rates, 10, 32-33, 61-62  
     and life expectancy, 57-58

Mortality  
and marital status, 59  
ratios, 12, 117, 160  
statistics, 32-34, 61  
from tuberculosis, 55-57

Multiphasic Health Checkup Evaluation Study, 134-136, 212

Multiphasic screening (see Screening)

Multiple correlation, 161

Multiple logistic method, 161

Multiple regression, 161

Multiple Risk Factor Intervention Trial, 113

Multiple sclerosis, North-to-South gradient in, 64-65

Multivariate analysis, 161

Myocardial infarction (see Heart disease)

National Health Survey, 36-37  
study of hypertension symptoms, 190

National Heart and Lung Institute, 112

National Institutes of Health, 113  
research grant applications, 172

Natural experiments, 46

Natural history of disease, 139-140

Nephritis (see Kidney disease)

Newburgh-Kingston (N.Y.)  
Caries-Fluorine Study, 132-133

Nonresponse:  
in Framingham Heart Study, 110-111  
to questionnaires, 34

Normal values, 191-194  
definitions of, 191  
determination of normal limits, 191-194

North-to-South gradient of multiple sclerosis, 64-65

Numerator cases, 66

Numerator data, 196-197

Nutritional-deficiency diseases and socioeconomic status, 60

Obesity, 19, 44-45, 48-49, 58, 113, 194-195

Objectivity of authors, 199

Observational studies (see Studies)

Observations:  
clinical, 26-28, 109  
in epidemiology, 23-42

Occupation, 53, 60, 85-86

Occupational exposures, 82

Oral contraceptives (see Contraceptives)

Osteoarthritis (see Arthritis, degenerative)

Outbreak (see Epidemics)

Pain, low back, in example of spurious relationship, 156-157, 159-160

Pasteurization of milk in preventing disease, 209

Pathologists' observations, 28

Patient care, 1  
relation to epidemiology, 187-200

Percentages, 8

Percentiles, 19-20

Periodic time trends (see Time pattern of disease occurrence)

Peripheral vascular disease in Framingham Heart Study, 111

Person, personal characteristics and disease, 52-60

Person-to-person spread of disease, 68, 70, 74

Person-years of observation, 107-108, 116

Pesticide:  
cohort exposed to, 105  
as environmental hazard, 204

Phthisis, as tuberculosis manifestation, 6

Physical activity, 86, 113, 209

Physical examinations (see Examinations)

Physician (see Clinician)

Place, location of disease occurrence 52, 60-67, 152-153

Placebo:  
in antihypertensive drug trial, 144  
in poliomyelitis vaccine trial, 128-130

Placebo effect, 142, 196

Poliomyelitis 45-46, 60, 128-131  
vaccine trial, 128-131

Population at risk, 9-11, 86, 105, 111  
(See also Denominators)

Portacaval shunt operation (Boston Interhospital Liver Group Study), 143-144

Post hoc explanations, 118

Prediction of study outcomes, importance of, 117-118

Pregnancy, 58-59, 95-97

Prevalence:  
as determined by incidence and duration, 81  
of disease as related to results of screening, 214-215

Prevalence cases, 81

Prevalence rates (see Rates)

Prevalence studies (see Studies)

Prevention of disease, 1, 5, 6, 98, 114, 122-126, 134, 138-139, 194-195, 209-210  
by large-scale social and environmental change, 209-210  
prevention of accidents, 98

Preventive medicine, 122  
office practice of, 194-195, 209-210

Probability, 26

Probability (*p*) values, 26

Prognosis of disease, 139-141

Proportions, 8, 13-14, 21, 139

Prospective studies (see Studies)

Protocol for a study:  
contents of, 172-173  
later use of, 185  
necessity for writing, 171-172  
preparation of, 171-173

Psychology, as complex field, 118

Psychosocial factors, 113  
study of, 170

Pulmonary embolism (see Thromboembolic disease)

Pulmonary function, 83  
tests of, 82  
vital capacity, 113

Qualitative attributes (see Attributes)

Quantiles, 18-20, 22

Quantitative attributes (see Attributes)

Quartiles, 19-21, 108

Questionnaires, 34-36, 38, 82, 134  
overreporting of disease symptoms, 35-36  
response and nonresponse, 34-36  
standardized respiratory, 82  
use in office practice, 194

Quintiles, 19

Race, as factor in disease occurrence, 53, 58-59, 66-67, 84-86, 162

Racial differences:  
in coronary heart disease, 84-86  
in hypertension, 59  
in rheumatic fever, 66-67  
in sickle-cell anemia, 58  
in skin cancer, 58

Radiation exposure, 46, 81, 105  
ethical problems, 114  
groups exposed and studied, 115  
maternal, 81, 114-117  
problems in determining, 180

Radiologists, 28-29  
observations of, 28-29  
mortality in, 114-117

Random numbers, 78

Random samples (see Samples)

Randomized control groups in experiments, 123-125, 131, 133, 143-144

Ranges of distributions, 18  
interquartile (see Interquartile range)

Ranking of individuals in a group, 19, 24-25

Rapport with community in specific studies, 84, 112

Rates, 8-13, 21  
age-adjusted, 159-161  
age-specific, 10, 161  
attack, 67, 203  
case fatality, 10  
comparison of, 11-13, 21  
cure, 145  
differences in, 11-12, 21  
disability, 145  
expected, 12-13, 160  
incidence, 9, 21, 81, 106-107, 118, 203  
maternal mortality, 11  
as measures of disease outcomes, 145  
mortality or death, 10, 32-33, 99, 145  
other, 9-11  
period prevalence, 9-10  
prevalence, 8-9, 21, 81, 145  
ratios of, 12-13, 21  
recovery, 145  
survival, 145

Ratios:  
morbidity, 12-13, 20-21, 160  
mortality, 12, 117, 160  
of rates (see Rates)

Risk, 12

Record-linkage, 119

Regional comparisons within countries, 64-65, 152-153  
 Registrar General for England and Wales, 60  
 Relationships, 37-45, 77, 119  
 detection of, in poor quality data, 38-42  
 linear, 151  
 Relative risk (*see* Risk of disease)  
 Reliability of observations, 24-25, 27, 30  
 Religion, 53  
 Respiratory disease, chronic, 81-83  
 Retrospective studies (*see* Studies)  
 Rheumatic fever, 3, 64, 66-67, 140  
 Risk of disease, 104, 107, 113  
 gradient of, 165  
 need for denominator to determine, 196-198  
 relative, 12, 94, 163  
 from case-control studies, 94, 97  
 Risk factors, 109, 112-114  
 combinations of, 113  
 Rural areas, 64, 110  
 providing health care to, 216

Salt, dietary, 62  
 Sample size determination, 127  
 Samples:  
 cluster, 78-79, 82  
 random, 26, 82-83, 85, 135  
 simple random, 78, 82  
 stratified random, 78, 82, 85  
 systematic, 79, 82, 110, 135  
 (*See also* Sampling)  
 Sampling:  
 of families, 111  
 by households, 79  
 methods of, 78-79  
 in multiple stages, 79, 82  
 in selecting control groups, 92  
 Sampling variation, 25-26, 38, 92, 127  
 Scleroderma, survival with, 146-147  
 Screening, 211-216  
 for high risk, 215  
 multiphasic, 34, 212, 215-216  
 expanding role of, 215-216  
 Seasonal variation in disease occurrence, 3, 73-74, 206  
 Secular trends, 67, 74-75

Selection:  
 of data to prove a point, 199  
 of papers for publication, 199-200  
 Self-selection, 117, 126  
 Sensitivity of a test:  
 definition of, 192  
 in screening, 213-214  
 Sequential analysis, 127-128  
 Sex, as factor in disease occurrence, 53, 58, 83-85, 112, 155  
 "Shoe-leather" epidemiology, 99  
 Smoking (*see* Cigarette smoking)  
 Social change to prevent disease, 209-210  
 Social class (*see* Socioeconomic status)  
 Socioeconomic status, 85  
 as factor in disease occurrence, 53, 59-60, 66-67, 85-86, 116  
 and infant mortality, 60-61  
 Specifications of variables in data analysis, 158  
 Specificity of a test:  
 definition of, 192  
 in screening, 213-214  
 Spouse pairs, 111  
 Standard deviations, 17-18, 20, 22, 94, 179  
 Standardization (*see* Adjustment)  
 Statistical associations, 150-167  
 as cause-and effect relationships, 162-166  
 consistency of, 163-165  
 due to chance, 154  
 between diseases, 151, 166-167  
 general applicability of, 162  
 measures of, 150-151  
 specificity of, 165-166  
 spurious or secondary, 154-161, 163-164, 170  
 control of, in data analysis, 158-161  
 prevention of, 157-158  
 strength of, 163  
 time sequence of, 163  
 Statistical methods for multiple variables, 161  
 Statistical significance:  
 versus biological significance, 154  
 tests of, 17, 26, 123, 154  
 Statistics, 13-14  
 (*See also* Vital statistics)  
 Stomach ulcer (*see* Ulcer)

Strata (stratification) of populations, 78-79, 124  
 Stratified samples (*see* Samples)  
 Strokes:  
 decubitus ulcers after, 140  
 diagnosing, in incidence studies, 106, 109  
 in Framingham Heart Study, 111, 113  
 hypertension and, 39-42, 144  
 in Japanese, 62-63  
 mental status following, 92  
 oral contraceptives and, 98  
 questionnaire versus neurologists' diagnosis, 38  
 in Veterans Administration study, 144  
 Studies:  
 analytic, 46-47, 88, 102, 140-142  
 case-control, 46-50, 77, 88-103, 108, 140-141, 163, 203  
 descriptive, 46-47, 52-76, 84, 109, 139  
 to evaluate changes in health care, 216-217  
 experimental, 44-46, 113-114, 121-137  
 blind, 126-128  
 double-blind, 126-127  
 exploratory, 103  
 how to carry out, 169-186  
 how to report results of, 184-186  
 incidence, 46, 48-50, 77, 80, 86, 94-95, 104-121, 140, 163, 203  
 observational, 44-46, 104, 113, 121-122  
 prevalence, 46-50, 77-86, 88-90, 94-95, 105, 107-108, 140, 163  
 as first stage of incidence study, 86, 105  
 prospective, 46, 49-51, 104, 118-119  
 retrospective, 46, 49-51, 115, 119  
 retrospective cohort (retrospective incidence), 115, 119  
 retrospective-prospective, 50  
 types of, 43-51  
 Sudden death, 62, 80, 113, 170  
 Surveys:  
 household, 36-37  
 National Health Survey, 36-37, 190  
 Survival, 145-148  
 duration of, 145-146  
 expected, 147  
 rates of, 145  
 starting times for determining, 148  
 Survival curves, 146-148

Ulcer:  
 decubitus, 140  
 peptic, 165  
 stomach, 60

by actuarial or life-table method, 147-148  
 Susceptible persons (to disease), 68, 70  
 Symptoms and disease diagnosis, 189-191

Tables:  
 blank, as aid in data analysis, 181-182  
 complete, 182-183  
 fourfold (two-by-two), 39-40, 154  
 incomplete, 182  
 preparation of, 181-183, 185-186  
 Terciles, 19  
 Therapeutic trials, 142-145  
 Therapy, enthusiasm over, 143  
 Thromboembolic disease, 95-98, 164  
 Thrombophlebitis (*see* Thromboembolic disease)  
 Time pattern of disease occurrence, 67-75, 153  
 assessing time trends by prevalence studies, 84  
 long-term (secular) trends, 67, 74-75  
 periodic trends, 67, 73-74  
 short-term trends, 67-73  
 Time sequence of factors and disease, 49-50, 81, 108  
 Tobacco (*see* Cigarette smoking)  
 Tooth decay (*see* Dental caries)  
 Tooth enamel, mottled, 131, 133  
 Traumatic injuries, 97-98  
 Tuberculosis:  
 BCG vaccination, 44-45  
 causal versus descriptive names for, 6  
 causation of, 3  
 on chest x-rays, 29-30  
 cohort versus cross-sectional age trends, 55-57  
 decline in mortality from, 5, 207  
 social class gradient, 60  
 study in Framingham, 110  
 variety of manifestations, 166  
 Typhoid carriers, detecting, 204

U.S. Public Health Service, 110  
Upper respiratory infections, 74  
Urban areas, 64  
Uric acid distribution, 15-18

Vaccination, 204  
BCG, 44-45  
poliomyelitis, 45-46, 128-131  
(*See also* Immunization)  
Vaccine, 2-3, 45  
Validity of observations, 24-25, 38  
Variables:  
dependent, 44-45  
dichotomous, 39  
independent, 44-46  
qualitative, recording of, 176-179  
quantitative, 13-21, 94, 151  
- matching of, 93  
- recording of, 175-176, 179  
relationships between, 44-45, 151  
Variations in measurements, 25-26  
within an individual, 25  
among individuals, 25  
measurement errors, 24-25  
due to sampling, 25-26  
among subgroups, 25  
Vectors, 68, 74  
Vehicles of disease transmission, 68

Venereal disease, 31, 36, 53  
Veterans Administration study of  
hypertension therapy, 144  
Vital statistics, 61, 133  
surveillance of, 206  
Volunteers, 134, 162  
in Framingham Heart Study, 111, 162

Water, as vehicle of disease  
transmission, 68, 74  
Water supplies:  
contaminated, 70, 204  
fluoride in, 53, 131-133, 209  
Waterborne gastrointestinal infections, 74  
Weather and traffic accidents, 101-102  
Web of causation, 3-5  
Whooping cough, decline in mortality  
from, 208

X-rays, 29-30  
chest, 29-30, 85, 111, 188-189  
dental, 132-133  
gallbladder, 190  
knee, 48-49  
showing renal stones, 89  
(*See also* Radiation exposure;  
Radiologists)